The pharmaceutical sector is recently in the focus of the academic literature, as it becomes more and more an important topic on the European level. Especially the relationship between patent and competition law can lead to problems and is consistently discussed. In September 2008 the ECJ had to make a decision in a case between a pharmaceutical manufacturer and his distributors, in which both fields of law played an important role. Because of these recent developments the objective of this thesis is to analyse the current relation between patent and competition law by laying the emphasis on the phenomenon of parallel trade. This work will focus on the abovementioned Lelos Case and its implications for the principle of exhaustion.
It does not deal with patent or competition law in detail, but contains the most important aspects in order to explain the consequences of the ECJ’s decision. Furthermore, the aspect of costs for research and development cannot be described extensively, but will be mentioned with regard to Lelos. The reason for that is the predetermined length of the thesis and the specific question, which the author has developed as a result of the Lelos Case.
At first the relevant conditions on the pharmaceutical market will be briefly shown (2.) in order to explain why especially in this sector parallel trade is such an important issue. Then, the general tension between patent and competition law will be described, by depicting the most important characteristics and jurisprudence in both fields of law (3.). The next chapter deals with the Lelos Case (4.). The decision to illustrate AG Colomer’s opinion is the result of his different approach to the case in comparison to the point of view of the defendant (i.e. GlaxoSmithKline). After that, a result regarding the impact of the ECJ’s decision on parallel trade and the principle of exhaustion will be given (5.). In this chapter it will be shown how legal writers estimate the consequences and evolutions of the Lelos Case in practice.
This thesis shall show how the ECJ has influenced parallel trade in patented pharmaceuticals in the future and what this means for the so far in EC law highly protected principle of exhaustion.
Table of Contents
1. Introduction
2. Special characteristics of the pharmaceutical market
3. Tension between Patent law and Competition law
3.1. Patent law
3.1.1. Purpose of a patent
3.1.2. The principle of exhaustion and parallel trade
3.2. Competition Law
3.2.1. Art. 81 EC
3.2.2. Art. 82 EC
3.3. Intermediary result
4. The Lelos case
4.1. Facts of the case
4.2. Opinion of AG Colomer
4.3. The ECJ’s decision
5. Consequences of the Lelos case
6. Conclusion
7. Bibliography
Objectives and Research Focus
This thesis analyzes the evolving relationship between patent law and competition law in the European Union, specifically focusing on how pharmaceutical manufacturers attempt to restrict parallel trade. The primary research goal is to evaluate the implications of the landmark "Lelos" case on the principle of exhaustion and to determine whether manufacturers can effectively limit supply to prevent parallel trade under the guise of legitimate business interests.
- The intersection of patent protection and competition law in the EU pharmaceutical sector.
- The mechanics and impact of parallel trade on market price differentials.
- Legal analysis of Article 81 and Article 82 EC in the context of supply restrictions.
- Critical examination of the ECJ’s decision in the Lelos case.
- The future viability of the principle of exhaustion for patented medicinal products.
Excerpt from the Book
4.3. The ECJ’s decision
At first, the ECJ agrees with AG Colomer that the refusal to supply can constitute an abuse, as the aim and effect is to limit parallel trade. It is apparent that the Court explicitly stresses the importance of the phenomenon of parallel imports and its protection in Community law. According to the ECJ parallel imports encourage trade and help to reinforce competition. Moreover, it states that in case of patented pharmaceuticals there is just one form of price competition, namely between the manufacturer and its distributors or between the parallel traders and national distributors. These propositions are in line with the courts previous judgments as one could see in chapter 3. Parallel trade and, in connection with it, the principle of exhaustion had always a very important status in EC law. That’s why the further argumentation and the final decision seem to be rather surprising. In the following the ECJ highlights that a company has the right to protect its own commercial interests. This is also an aspect not unknown to EC law, as it was already stressed many years ago in the case United Brands. One can say that the Court is definitely aware of both interests, which conflict in Lelos. On the one hand, the interest of the pharmaceutical manufacturer, and on the other hand, the one of the distributors and free competition in general.
Summary of Chapters
1. Introduction: Outlines the objective of the thesis, which is to analyze the tension between patent and competition law with a focus on the Lelos case and parallel trade.
2. Special characteristics of the pharmaceutical market: Explains why parallel trade is particularly lucrative in the pharmaceutical sector due to price discrepancies and the regulatory environment.
3. Tension between Patent law and Competition law: Discusses the fundamental conflict between the exclusivity granted by patents and the EU goal of free competition, including an analysis of key ECJ cases.
4. The Lelos case: Examines the facts, the opinion of Advocate General Colomer, and the final decision of the ECJ regarding supply restrictions.
5. Consequences of the Lelos case: Analyzes the practical impact of the ECJ ruling on future parallel trade and the "ordinary orders" criterion.
6. Conclusion: Summarizes findings, noting that the ECJ has potentially weakened the principle of exhaustion by allowing manufacturers to restrict supply under Article 82 EC.
7. Bibliography: Lists the academic literature and legal sources used in this research.
Keywords
Parallel trade, Pharmaceutical market, Patent law, Competition law, Principle of exhaustion, Lelos case, Article 82 EC, Supply restrictions, ECJ, Market regulation, Research and Development, Ordinary orders, European Union, Patent protection, Exclusive rights.
Frequently Asked Questions
What is the core focus of this academic work?
The work primarily examines the legal conflict between patent law and EU competition law, specifically concerning the ability of pharmaceutical companies to restrict parallel trade via supply limitations.
Which specific areas of law are central to the study?
The study centers on Intellectual Property (Patent) Law and EU Competition Law (specifically Articles 81 and 82 EC).
What is the primary objective of this thesis?
The objective is to determine how the Lelos case has impacted the "principle of exhaustion" and whether it allows manufacturers to bypass competition law by justifying supply cuts.
What research methodology does the author employ?
The author uses a qualitative legal analysis, reviewing jurisprudence from the European Court of Justice (ECJ) and the Court of First Instance (CFI) to evaluate shifting trends in legal interpretations.
What does the main body of the text cover?
It covers the market characteristics of the pharmaceutical industry, the historical tension between patents and competition, a detailed analysis of the Lelos case proceedings, and its broader implications.
Which keywords best characterize this research?
Key terms include Parallel trade, Principle of exhaustion, Lelos case, Pharmaceutical market, and Supply restrictions.
What is the "ordinary orders" criterion established in the Lelos case?
It is a standard used by the ECJ to allow manufacturers to refuse to supply orders that exceed what is deemed "ordinary" for a national market, effectively permitting a form of supply control.
Does the author conclude that the Lelos case favors the pharmaceutical industry?
Yes, the author concludes that the ECJ’s decision is largely advantageous for pharmaceutical manufacturers, as it provides them with a foundation to limit exports without necessarily violating Article 82 EC.
- Arbeit zitieren
- LL.M. Anja Balitzki (Autor:in), 2009, The end of parallel trade with patented pharmaceuticals?, München, GRIN Verlag, https://www.hausarbeiten.de/document/137580
